Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde, Sigrid, Kristoffersen, Einar K, Sapkota, Dipak et al.·PloS one·2016
Researchers tested whether a drug called rituximab, which removes B cells (a type of immune cell) from the blood, helps ME/CFS patients by examining immune system changes. They found that some ME/CFS patients had higher levels of a substance called BAFF that activates B cells, but this didn't predict who would improve with treatment. While some patients did get better with rituximab in earlier trials, the immune cell changes measured in this study didn't fully explain why.